STOCK TITAN
  1. Home
  2. News
  3. NAMS

NewAmsterdam Pharma Company N.V. Ordinary Shares - NAMS STOCK NEWS

Welcome to our dedicated page for NewAmsterdam Pharma Company N.V. Ordinary Shares news (Ticker: NAMS), a resource for investors and traders seeking the latest updates and insights on NewAmsterdam Pharma Company N.V. Ordinary Shares stock.

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) is a leading late-stage biopharmaceutical company headquartered in the Netherlands, dedicated to revolutionizing patient care for metabolic diseases. The company focuses on populations where existing therapies are insufficient or poorly tolerated. Central to NewAmsterdam's innovation is obicetrapib, a next-generation, oral, low-dose CETP inhibitor designed to address limitations of current LDL-C lowering treatments.

As of 2024, NewAmsterdam is at the forefront of clinical development, with multiple pivotal Phase 3 trials underway. The company is optimistic about its potential to transform cardiovascular disease (CVD) treatment. Recent milestones include the enrollment completion of the BROOKLYN and BROADWAY Phase 3 trials, both aimed at evaluating obicetrapib’s efficacy as an adjunct to maximally tolerated statin therapy. Additionally, the company's PREVAIL cardiovascular outcomes trial and the newly initiated TANDEM Phase 3 trial are progressing, assessing obicetrapib's combination with ezetimibe for patients with elevated LDL-C levels.

In 2023, NewAmsterdam reported promising outcomes from its Phase 2 trials, including the ROSE2 trial, which combined obicetrapib with ezetimibe, demonstrating a significant 63% reduction in LDL-C levels. The company's robust clinical pipeline showcases obicetrapib’s strong tolerability profile, having tested the drug in over 800 patients with elevated lipid levels and observing statistically significant results without severe adverse events.

Looking to the future, NewAmsterdam is well-positioned financially, forecasting sufficient cash runway through 2026 to support its ambitious development plans. The company is also actively preparing for the global launch of obicetrapib, pending necessary regulatory approvals. This includes strategic investments in its commercial organization to ensure comprehensive market readiness.

NewAmsterdam’s commitment to innovation is further reinforced by strong intellectual property protection for obicetrapib, with patents extending until July 2043. This robust IP portfolio underscores the company's dedication to maintaining a competitive edge in the biopharmaceutical industry.

For more information, visit NewAmsterdam Pharma Company’s investor relations page or contact their media and investor relations teams for the latest updates.

News

NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease

Rhea-AI Summary
NewAmsterdam Pharma Company N.V. (NAMS) has successfully achieved its enrollment target of 9,000 patients for the Phase 3 PREVAIL cardiovascular outcomes trial evaluating obicetrapib, a potential treatment for patients with cardiovascular disease. The company plans to extend enrollment to accommodate strong interest, with expectations to randomize over 9,000 patients by the end of April. Driven by the need for more effective therapies for patients with elevated LDL-C levels, NewAmsterdam aims to demonstrate obicetrapib's potential to reduce major adverse cardiac events and improve outcomes for those at risk of serious cardiovascular conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.37%
Tags
clinical trial
-
News

BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors

Rhea-AI Summary
BioAge Labs, Inc. appoints Michael Davidson, MD, CEO of NewAmsterdam Pharma, to its board of directors. Davidson's expertise in cardiometabolic research and clinical development will aid in advancing lead compound azelaprag into Phase 2 trials for obesity treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.37%
Tags
management
-
News

NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer

Rhea-AI Summary
NewAmsterdam Pharma Company N.V. appoints Juliette Audet as Chief Business Officer and announces her resignation from the Board of Directors. The company aims to develop oral, non-statin medicines for patients at risk of cardiovascular disease with elevated LDL-C.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.64%
Tags
management
News

NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress

Rhea-AI Summary
NewAmsterdam Pharma Company N.V. (NAMS) to present additional data from the Phase 2 ROSE2 clinical trial at the 2024 American College of Cardiology Congress. The trial evaluated obicetrapib in combination with ezetimibe for patients at risk of cardiovascular disease with elevated LDL-C. New data will show the impact on small dense LDL-C, a predictor of future cardiovascular events. NewAmsterdam also initiated the TANDEM Phase 3 trial for patients with HeFH and/or ASCVD. Details of the presentation include session title, date/time, location, and presentation title.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
conferences clinical trial
-
News

NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD

Rhea-AI Summary
NewAmsterdam Pharma initiates TANDEM Phase 3 trial for obicetrapib and ezetimibe FDC in patients with high cholesterol levels and cardiovascular disease risk, aiming to improve LDL-C levels. The trial is expected to report topline data in Q1 2025, alongside BROOKLYN and BROADWAY studies. NewAmsterdam progresses with its Phase 3 trials, optimistic about the potential of their novel CETP inhibitor franchise.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.89%
Tags
clinical trial
-
News

NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update

Rhea-AI Summary
NewAmsterdam Pharma Company N.V. (NAMS) announces positive clinical trial progress, upcoming milestones, and financial results for 2023. They reported encouraging Phase 2 trial data for obicetrapib, with plans for Phase 3 trials and a pivotal trial for a fixed-dose combination. The company completed a successful public offering, raising $202 million. Despite a decrease in cash and revenue, R&D and SG&A expenses increased, resulting in a higher net loss for 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.52%
Tags
earnings
News

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March

Rhea-AI Summary
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) announces participation in three upcoming investor conferences to present their late-stage, clinical biopharmaceutical developments for cardiovascular disease. Live webcasts and archived replays will be available for investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.67%
Tags
conferences
-
News

NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Rhea-AI Summary
NewAmsterdam Pharma Company N.V. (NAMS) announces the pricing of a public offering, expecting to raise approximately $175.3 million to fund the development of oral, non-statin medicines for patients at risk of cardiovascular disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.25%
Tags
offering
-
News

NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants

Rhea-AI Summary
NewAmsterdam Pharma Company N.V. (NAMS) announces a public offering of ordinary shares and pre-funded warrants. The underwritten public offering aims to raise capital for the late-stage clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.25%
Tags
offering
News

NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Rhea-AI Summary
NewAmsterdam Pharma Company N.V. (NAMS) announced that CEO Michael Davidson and CFO Ian Somaiya will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on February 7, 2024. The company is a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated LDL-C. The webcast will be available through the investor relations section of the NewAmsterdam Pharma website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.01%
Tags
conferences

FAQ

What is the current stock price of NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)?

The current stock price of NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) is $25.5 as of December 20, 2024.

What is the market cap of NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)?

The market cap of NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) is approximately 2.7B.

What is NewAmsterdam Pharma Company N.V.'s primary focus?

NewAmsterdam Pharma Company N.V. focuses on developing therapies for metabolic diseases where existing treatments are inadequate or poorly tolerated.

What is obicetrapib?

Obicetrapib is an oral, low-dose CETP inhibitor being developed by NewAmsterdam Pharma as a next-generation LDL-C lowering treatment.

What are the key clinical trials NewAmsterdam is conducting?

NewAmsterdam is conducting several pivotal Phase 3 trials, including BROOKLYN, BROADWAY, PREVAIL, and TANDEM, to evaluate obicetrapib and its combination with ezetimibe.

What significant milestones has NewAmsterdam achieved recently?

Recent milestones include completing enrollment for the BROOKLYN and BROADWAY trials, initiating the TANDEM trial, and achieving strong results in Phase 2 trials.

How does NewAmsterdam plan to commercialize obicetrapib?

NewAmsterdam is investing in its commercial organization and preparing for a global launch of obicetrapib, pending regulatory approvals.

What financial outlook does NewAmsterdam have?

NewAmsterdam projects that its existing cash will support operations through 2026, aligning with the readout of its three pivotal Phase 3 trials.

What are NewAmsterdam's goals for 2024?

In 2024, NewAmsterdam aims to report top-line results from its Phase 3 trials and advance the commercial launch preparations for obicetrapib.

What is the significance of NewAmsterdam's intellectual property portfolio?

NewAmsterdam holds patents protecting obicetrapib until July 2043, ensuring long-term competitive advantage and innovation in LDL-lowering therapies.

Where is NewAmsterdam Pharma based?

NewAmsterdam Pharma Company N.V. is based in Naarden, the Netherlands.

Who should I contact for more information about NewAmsterdam?

For more information, reach out to Matthew Philippe, Jen Gordon, or Hannah Deresiewicz via the contact details provided on NewAmsterdam’s investor relations page.

Stock NAMS logo
NewAmsterdam Pharma Company N.V. Ordinary Shares

Nasdaq:NAMS

NAMS Rankings

#1726 Ranked by Market Cap
N/A Ranked by Dividends

NAMS Stock Data

2.73B
91.19M
0.25%
89.59%
1.09%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NARRDEN